(Yardley, PA, USA). Support for this assistance was funded by F. Hoffmann–La Roche, Basel, Switzerland. Disclosures. Andrea Rubbert-Roth reports honoraria and advisory board fees from Roche and honoraria
Joerg Wendler 0 Gerd R Burmester Helmut Srensen Andreas Krause Constanze Richter Hans-Peter Tony Andrea Rubbert-Roth Peter Bartz-Bazzanella Siegfried Wassenberg Iris Haug-Rost Thomas Drner 0
tocilizumab. Matthias Laudes and Andrea Rubbert-Roth received lecture fees from the same company. The company does not alter the adherence to all the PLoS ONE policies on sharing data and material. The
Introduction Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology...